These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34024887)

  • 1. Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials.
    Yin DG; Ding LL; Zhou HR; Qiu M; Duan XY
    Endocr J; 2021 Jun; 68(6):739-742. PubMed ID: 34024887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
    Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I
    Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
    Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
    Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
    Husain M; Bain SC; Jeppesen OK; Lingvay I; Sørrig R; Treppendahl MB; Vilsbøll T
    Diabetes Obes Metab; 2020 Mar; 22(3):442-451. PubMed ID: 31903692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
    Strain WD; Frenkel O; James MA; Leiter LA; Rasmussen S; Rothwell PM; Sejersten Ripa M; Truelsen TC; Husain M
    Stroke; 2022 Sep; 53(9):2749-2757. PubMed ID: 35582947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
    Mann JFE; Hansen T; Idorn T; Leiter LA; Marso SP; Rossing P; Seufert J; Tadayon S; Vilsbøll T
    Lancet Diabetes Endocrinol; 2020 Nov; 8(11):880-893. PubMed ID: 32971040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.
    Aroda VR; Erhan U; Jelnes P; Meier JJ; Abildlund MT; Pratley R; Vilsbøll T; Husain M
    Diabetes Obes Metab; 2023 May; 25(5):1385-1397. PubMed ID: 36700417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
    Husain M; Consoli A; De Remigis A; Pettersson Meyer AS; Rasmussen S; Bain S
    Cardiovasc Diabetol; 2022 Apr; 21(1):64. PubMed ID: 35484580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
    Jendle J; Birkenfeld AL; Polonsky WH; Silver R; Uusinarkaus K; Hansen T; Håkan-Bloch J; Tadayon S; Davies MJ
    Diabetes Obes Metab; 2019 Oct; 21(10):2315-2326. PubMed ID: 31215727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaglutide once-weekly: improved efficacy with a new safety warning.
    Coon SA; Crannage EF; Kerwin LC; Guyton JE
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
    Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.
    Yabe D; Deenadayalan S; Horio H; Kaneto H; Jensen TB; Terauchi Y; Yamada Y; Inagaki N
    J Diabetes Investig; 2022 Jun; 13(6):975-985. PubMed ID: 35112504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
    Verma S; Fainberg U; Husain M; Rasmussen S; Rydén L; Ripa MS; Buse JB
    Diabetes Obes Metab; 2021 Jul; 23(7):1677-1680. PubMed ID: 33606902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.
    Araki E; Terauchi Y; Watada H; Deenadayalan S; Christiansen E; Horio H; Kadowaki T
    Diabetes Obes Metab; 2021 Dec; 23(12):2785-2794. PubMed ID: 34472698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
    Wang F; Mao Y; Wang H; Liu Y; Huang P
    Clin Drug Investig; 2022 Jan; 42(1):17-28. PubMed ID: 34894326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical guidance for use of oral semaglutide in primary care: a narrative review.
    Morales J; Shubrook JH; Skolnik N
    Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.